Absci Corp

Absci Corp is a clinical-stage biopharmaceutical company that uses an AI-native approach to develop antibody therapeutics. The company's integrated drug creation platform combines Origin-1, a generative design model, with rapid validation using its lab-in-the-loop system. Absci focuses on underexplored biological mechanisms where there is a high unmet medical need and low competition. The company has advanced its first two programs from AI design to an Investigational New Drug (IND) application (or foreign equivalent) in approximately two years, with a total investment of about $15 million per program. This compares to an industry average of 4-6 years at a cost greater than $50 million. Absci's lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life for patient-friendly dosing. ABS-201 is being developed for two indications: androgenetic alopecia (AGA) and endometriosis. Androgenetic alopecia, also known as pattern hair loss (PHL), affects approximately 80 million people in the United States. ABS-201 is currently being evaluated in the HEADLINE™ Phase 1/2a clinical trial (NCT07317544) for AGA. The company has dosed the first three single ascending dose cohorts with a favorable safety profile to date, and interim proof-of-concept data, including exploratory efficacy endpoints, are expected in the second half of 2026. For endometriosis, a chronic condition estimated to affect approximately 10% of women of reproductive age worldwide, Absci plans to initiate a Phase 2 clinical trial of ABS-201.